{
    "title": "Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis",
    "pmid": "39604537",
    "pmcid": "PMC11603346",
    "study_parameters": [
        {
            "Study Parameters ID": 1452720988,
            "Variant Annotation ID": 1452720980,
            "Study Type": "meta-analysis",
            "Study Cases": 504.0,
            "Study Controls": null,
            "Characteristics": "2 studies (Carr, Giacomelli): DILI",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.42,
            "Confidence Interval Start": 0.21,
            "Confidence Interval Stop": 0.84,
            "Biogeographical Groups": "Multiple groups, \"The meta-analysis of the link between CYP2B6 genotypes and EFV-induced liver injury was only derived from the African population, as well as NVP-induced liver injury were obtained from only African and Caucasian populations. ",
            "Variant Annotation ID_norm": "1452720980"
        },
        {
            "Study Parameters ID": 1452721009,
            "Variant Annotation ID": 1452721001,
            "Study Type": "meta-analysis",
            "Study Cases": 795.0,
            "Study Controls": null,
            "Characteristics": "3 studies (Yimer 2011, Mugusi, Yimer 2012): DILI",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.003",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.94,
            "Confidence Interval Start": 1.24,
            "Confidence Interval Stop": 3.01,
            "Biogeographical Groups": "Sub-Saharan African",
            "Variant Annotation ID_norm": "1452721001"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1452720980,
            "Variant/Haplotypes": "CYP2B6*1, CYP2B6*6",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 39604537,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "According to the results of the sensitivity analysis, the substantial relationships between the CYP2B6 *1/*6 allele and a combination of *1/*6 + *6/*6 alleles with a lower risk of NVP-induced liver injury were not attributable to chance. ",
            "Sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.",
            "Alleles": "*1/*6 + *6/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Drug-induced liver injury",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39604537",
            "Variant Annotation ID_norm": "1452720980"
        },
        {
            "Variant Annotation ID": 1452721001,
            "Variant/Haplotypes": "CYP2B6*1, CYP2B6*6",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 39604537,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Compared with normal metabolizers, CYP2B6 *6 carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15-2.90), 2.48 (1.28-4.79), and 1.94 (1.24-3.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as P value less than 0.05 (Table 2).",
            "Sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.",
            "Alleles": "*1/*6 + *6/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Drug-induced liver injury",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39604537",
            "Variant Annotation ID_norm": "1452721001"
        }
    ],
    "var_fa_ann": []
}